Emerging role of 18F-FDG PET/CT in Castleman disease: a review
Abstract Castleman disease (CD) describes a group of rare hematologic conditions involving lymphadenopathy with characteristic histopathology and a spectrum of clinical abnormalities. CD is divided into localized or unicentric CD (UCD) and multicentric CD (MCD) by imaging. MCD is further divided based on etiological driver into human herpesvirus-8-associated MCD, POEMS-associated MCD, and idiopathic MCD. There is notable heterogeneity across MCD, but increased level of pro-inflammatory cytokines, particularly interleukin-6, is an established disease driver in a portion of patients. FDG-PET/CT can help determine UCD versus MCD, evaluate for neoplastic conditions that can mimic MCD clinico-pathologically, and monitor therapy responses. CD requires more robust characterization, earlier diagnosis, and an accurate tool for both monitoring and treatment response evaluation; FDG-PET/CT is particularly suited for this. Moving forward, future prospective studies should further characterize the use of FDG-PET/CT in CD and specifically explore the utility of global disease assessment and dual time point imaging. Trial registration ClinicalTrials.gov, NCT02817997, Registered 29 June 2016, https://clinicaltrials.gov/ct2/show/NCT02817997.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Insights into imaging - 12(2021), 1 vom: 11. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Koa, Benjamin [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Castleman disease |
---|
doi: |
10.1186/s13244-021-00963-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR043466737 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR043466737 | ||
003 | DE-627 | ||
005 | 20230520001253.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210312s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13244-021-00963-1 |2 doi | |
035 | |a (DE-627)SPR043466737 | ||
035 | |a (DE-599)SPRs13244-021-00963-1-e | ||
035 | |a (SPR)s13244-021-00963-1-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Koa, Benjamin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Emerging role of 18F-FDG PET/CT in Castleman disease: a review |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Castleman disease (CD) describes a group of rare hematologic conditions involving lymphadenopathy with characteristic histopathology and a spectrum of clinical abnormalities. CD is divided into localized or unicentric CD (UCD) and multicentric CD (MCD) by imaging. MCD is further divided based on etiological driver into human herpesvirus-8-associated MCD, POEMS-associated MCD, and idiopathic MCD. There is notable heterogeneity across MCD, but increased level of pro-inflammatory cytokines, particularly interleukin-6, is an established disease driver in a portion of patients. FDG-PET/CT can help determine UCD versus MCD, evaluate for neoplastic conditions that can mimic MCD clinico-pathologically, and monitor therapy responses. CD requires more robust characterization, earlier diagnosis, and an accurate tool for both monitoring and treatment response evaluation; FDG-PET/CT is particularly suited for this. Moving forward, future prospective studies should further characterize the use of FDG-PET/CT in CD and specifically explore the utility of global disease assessment and dual time point imaging. Trial registration ClinicalTrials.gov, NCT02817997, Registered 29 June 2016, https://clinicaltrials.gov/ct2/show/NCT02817997 | ||
650 | 4 | |a Castleman disease |7 (dpeaa)DE-He213 | |
650 | 4 | |a Positron emission tomography/computed tomography |7 (dpeaa)DE-He213 | |
650 | 4 | |a Fluorodeoxyglucose F18 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Interleukin-6 |7 (dpeaa)DE-He213 | |
650 | 4 | |a HIV |7 (dpeaa)DE-He213 | |
700 | 1 | |a Borja, Austin J. |e verfasserin |4 aut | |
700 | 1 | |a Aly, Mahmoud |e verfasserin |4 aut | |
700 | 1 | |a Padmanabhan, Sayuri |e verfasserin |4 aut | |
700 | 1 | |a Tran, Joseph |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Vincent |e verfasserin |4 aut | |
700 | 1 | |a Rojulpote, Chaitanya |e verfasserin |4 aut | |
700 | 1 | |a Pierson, Sheila K. |e verfasserin |4 aut | |
700 | 1 | |a Tamakloe, Mark-Avery |e verfasserin |4 aut | |
700 | 1 | |a Khor, Johnson S. |e verfasserin |4 aut | |
700 | 1 | |a Werner, Thomas J. |e verfasserin |4 aut | |
700 | 1 | |a Fajgenbaum, David C. |e verfasserin |4 aut | |
700 | 1 | |a Alavi, Abass |e verfasserin |4 aut | |
700 | 1 | |a Revheim, Mona-Elisabeth |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Insights into imaging |d Berlin : Springer, 2010 |g 12(2021), 1 vom: 11. März |w (DE-627)SPR030999588 |w (DE-600)2543323-4 |x 1869-4101 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2021 |g number:1 |g day:11 |g month:03 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13244-021-00963-1 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 12 |j 2021 |e 1 |b 11 |c 03 |